Takeda Pharmaceuticals and leading Brazilian pharmaceutical company Multilab have signed an agreement for Takeda to acquire Multilab. Takeda hopes to finalise the acquisition by the second quarter of the fiscal year 2012. Takeda Brazil will spend 500 million (BRL) upfront to purchase Multilab and a further 40 million (BRL) in milestone payments to the owners of Multilab.
This acquisition will make Takeda one of the top ten pharma companies in Brazil. As a fast growing healthcare market, Multilab's best selling OTC products for cold and flu treatment will be a good addition to Takeda's existing presence in Brazil.
"This acquisition significantly reinforces Takeda's position in Brazil, which is the world's sixth largest economy and the biggest in South America," said Jostein Davidsen corporate officer, head of emerging markets commercial operations for Takeda. "Takeda has ambitious plans for growth in emerging markets. Brazil is our second largest emerging market after Russia/CIS in terms of revenues and the acquisition of Multilab is a clear signal of our intention to become a significant player both in Brazil and other high-growth markets."
To read more click here
To hear more about what's happening in the pharmaceutical industry go to BioPharma Australasia.